Acuity Strategic Partners is a comprehensive public affairs firm that specializes in building integrated strategies for life sciences companies, patients, and initiatives.
Acuity Strategic Partners understand your needs because we have walked in your shoes.
Patient advocacy and engagement has become critical to the life science community. From early development through FDA approval our team has over 50 years of combined experience in the industry and can assist you in the following areas:
Powerful. Strategic. Creative. Impactful. Effective.
Making changes to Medicare Part D that protect those with rare diseases By Michael Eging – – Thursday, October 31, 2019 https://www.washingtontimes.com/news/2019/oct/31/a-sledgehammer-on-a-fragile-market-when-a-scalpel-/ ANALYSIS/OPINION: When is the last time anyone heard of a government program not only working well, but also coming in under budget? Yet that is the reality of Medicare Part D, a market-driven program that provides…
By Jeff Oldham & Michael Hamrick December 04, 2018 Source: RealClear Health No one disputes that opioid addiction is a problem in need of varied solutions, as each person struggling is a story all his or her own. The opioid abuse epidemic has been a runaway freight train, barreling out of control through communities and lives, without much…
Phone: (202) 631-5752
Mike Eging: email@example.com
Michael Walsh firstname.lastname@example.org
Michael Hamrick email@example.com
Jeff Oldham firstname.lastname@example.org
Evan Kozlow email@example.com
Jeff has nearly 30 years of experience and success in developing and influencing the outcomes of federal health policy, with a focus on legislative and regulatory issues, including health care financing and delivery system reform; the Medicare and Medicaid programs; health equity/health disparities; federal funding, budget and appropriations; the Food, Drug and Cosmetic Act and the Affordable Care Act; rare disease, market access, value assessment, and other health care funding, coverage and payment matters. He represents biopharma and medical technology companies, patient and professional organizations, academic medical centers and a variety of healthcare related coalitions. Before creating his consulting firm in 1998, Jeff served in a leadership role in government affairs and policy at the Pharmaceutical Research and Manufacturers of America (PhRMA), representing the nation’s leading research based pharmaceutical and biotechnology companies. Jeff began his public policy career working on the professional staff of the United States Senate, serving as Committee Counsel to both the Health Education Labor and Pensions ( HELP) Committee and the Budget Committee, as well as Legislative Counsel to U.S. Senator Christopher J. Dodd ( D- Connecticut). Jeff earned his B.A. degree in History and Political Science ( magna cum laude) from Duke University and his J.D. degree from Duke University School of Law.